Search results for Caspase-3 antibody

Caspase 3 antibody [HMV307] HistoMAX™, Genetex, GTX639931

APC Anti-Caspase-3 antibody [E87], Abcam, AB305666

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CASP3/Caspase-3 Antibody (R3K78), AntibodySystem, RHE35909

Anti-CASP3/Caspase-3 Antibody (R3K79), AntibodySystem, RHE35910

Anti-CASP3/Caspase-3 Antibody (R3K80), AntibodySystem, RHE35911

Anti-CASP3/Caspase-3 Antibody (R3K81), AntibodySystem, RHE35912

PE Anti-Caspase-3 antibody [E87], Abcam, AB305665

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CASP3/Caspase-3 Antibody (R1W20), AntibodySystem, RHE35906

Anti-CASP3/Caspase-3 Antibody (R1W21), AntibodySystem, RHE35907

Anti-CASP3/Caspase-3 Antibody (R1W22), AntibodySystem, RHE35908